How can we assess the risk for sudden cardiac death to decide for primary prophylactic implantable cardioverter-defibrillator in patients with heart failure in 2022?

EP Europace Journal

16 May 2022

Organised by:

Read full article

Contributors

Jens Cosedis Nielsen

Jens Cosedis Nielsen

Author

Aarhus University Hospital Aarhus , Denmark

Nikolaos Dagres

Nikolaos Dagres

Author

You may be interested in

Congress Presentation

New concepts in sudden death risk stratification in the cardiomyopathies

27 August 2023

Congress Presentation

Real world data on long-term clinical outcomes in heart failure patients with reduced ejection fraction and implantable cardioverter defibrillator

22 May 2023

Congress Presentation

The risk of sudden cardiac death and use of SGLT2 inhibitors in patients with heart failure: a meta-analysis of pivotal randomized controlled trials including 17,911 patients

20 May 2023

Congress Session

Arrhythmias and devices

17 May 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources